Lynn Seely
CIK 1327111 · President and CEO · last filed 2026-08-11
Lynn Seely is a President and CEO who has filed 74 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing shows the insider sold $5.6K of LYEL on Aug 11, 2026. Across all open-market trades the lifetime net is −$37.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.16M
6
74
-$37.72M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LYEL | President and CEO | 73,488 | $13.55 | $995.8K | -$182.7K | 14 | 2026-08-11 |
| ABCL | Director | — | $11.20 | — | $0 | 1 | 2026-07-06 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 13,254 | $129.46 | $1.72M | $0 | 13 | 2025-07-21 |
| Myovant Sciences Ltd. (MYOV) Delisted | Principal Executive Officer | 1,889,992 | $26.98 | $50.99M | $0 | 5 | 2020-04-07 |
| MEDIVATION, INC. (MDVN) Delisted | Chief Medical Officer | 193,388 | — | — | -$37.38M | 40 | 2015-02-18 |
| MDV | Chief Medical Officer | 9,000 | $18.05 | $162.4K | -$160.2K | 1 | 2007-03-20 |
Recent Filings
74 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-11 | LYEL | Sell (S) | −390 | -$5.6K | EDGAR |
| 2026-07-06 | ABCL | Grant (A) | — | $0 | EDGAR |
| 2026-06-15 | LYEL | Sell (S) | −388 | -$7.3K | EDGAR |
| 2026-02-12 | LYEL | Sell (S) | −7,455 | -$174.4K | EDGAR |
| 2026-02-11 | LYEL | Mixed | +19,562 | -$10.1K | EDGAR |
| 2025-11-12 | LYEL | Sell (S) | −412 | -$6.6K | EDGAR |
| 2025-10-29 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2025-08-22 | LYEL | Mixed | +32,743 | -$76.5K | EDGAR |
| 2025-08-13 | LYEL | Sell (S) | −797 | -$8.3K | EDGAR |
| 2025-07-21 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | −17,156 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.